Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun;88(6):2480-2483.
doi: 10.1111/bcp.15350. Epub 2022 Apr 21.

Addressing the challenges of novel therapies in rare diseases with mechanistic perspectives: Missed opportunities or the way forward?

Affiliations
Free article
Editorial

Addressing the challenges of novel therapies in rare diseases with mechanistic perspectives: Missed opportunities or the way forward?

Janet Mifsud et al. Br J Clin Pharmacol. 2022 Jun.
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Micallef J, Blin O. Orphan drug designation in Europe: a booster for the research and development of drugs in rare diseases. Therapie. 2020 Apr;75(2):133-139. doi:10.1016/j.therap.2020.02.003
    1. Kesselheim AS, Solomon DH. Incentives for drug development-the curious case of colchicine. N Engl J Med. 2010;362(22):2045-2047. doi:10.1056/NEJMp1003126
    1. Groft SC, Posada de la Paz M. Preparing for the future of rare diseases. Adv Exp Med Biol. 2017;1031:641-648. doi:10.1007/978-3-319-67144-4_34
    1. Forbes TA, Brown BD, Lai C. Therapeutic RNA interference: a novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2022;88(6):2525-2538. doi:10.1111/bcp.14925
    1. Poddighe D, Romano M, Garcia-Bournissen F, Demirkaya E. Conventional and novel therapeutic options in children with familial Mediterranean fever: a rare autoinflammatory disease. Br J Clin Pharmacol. 2022;88(6):2484-2499. doi:10.1111/bcp.15149

Publication types

LinkOut - more resources